Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by pericles1on Mar 27, 2011 3:10am

314 Views

Post# 18346370

RE: RE: Latest Press Rlease!

Actually rjc I would accept your explanation if they had said that at the start of the trial. All this about a different population and Taxane exposed patients comes late in the trial and sounds a lot like hedging to me, but that's just my opinion. We will know soon enough if it's all peaches and cream and I have nothing to worry about. I envy you guys having no doubts about anything they do!

Bullboard Posts

Gold vs. bitcoin, where should you invest?